Results 231 to 240 of about 710,185 (341)

Pulmonary arterial hypertension treatment. A new era. [PDF]

open access: yesInt J Cardiol Congenit Heart Dis
Mouratoglou SA   +4 more
europepmc   +1 more source

Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs

open access: diamond, 2017
D. Yu. Platonov   +2 more
openalex   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul   +7 more
wiley   +1 more source

Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study [PDF]

open access: bronze, 2017
Michael Halank   +10 more
openalex   +1 more source

A systematic review of medication adherence and mortality in chronic disease: Implications for clinical guidelines and policy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Objectives This systematic review aims to investigate whether good medication adherence in adults with chronic conditions is associated with a lower mortality risk compared to poor adherence within published literature, and the extent to which this relationship is represented within South African policy and legislation.
Jessica Hamuy Blanco   +4 more
wiley   +1 more source

How the Latest Guidelines Are Changing the Diagnostic and Therapeutic Landscape of Arterial Hypertension. [PDF]

open access: yesJ Clin Med
Pastore MC   +7 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy